Mymetics Corp (MYMX)

[FALCON1]

Good morning! From 10-Q:

Currently the Company is working on two research projects with commercial partners. One project with Sanofi for influenza vaccines, for which we are currently conducting a pre-clinical studies and results are expected not before October 2018. A second project with Anergis SA, for which the Company is preparing virosome based vaccines which include Anergis peptides for treating birch pollen allergy, which will subsequently be tested in preclinical studies and results are not expected before the end of 2018. The Company is also working on a grant funded project in the field of HIV being the EU Horizon 2020 and Switzerland SERI which focusses on developing thermostable and cold chain independent virosome based vaccines (Maciviva project). This project will end by October 2018. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future through licensing.

https://www.sec.gov/Archives/edgar/data/927761/000165495418008862/mymx_10q.htm


Correct me if I'm wrong, this is the first time management mentions/acknowledges that the Horizon 2020 and SERI funded MACIVIVA project is HIV related although it is obvious since the consortium is using our HIV-1 vaccine. Could this be a hint of an upcoming material event?

later
regards,